{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:55:40Z","timestamp":1791291340127,"version":"4.3.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03155-2","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:12:00Z","timestamp":1791288720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic myeloid leukemia in a global context: confirmatory findings and novel discoveries from a refined Japanese Cohort"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6573-0536","authenticated-orcid":false,"given":"Mai","family":"Fujita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-3699","authenticated-orcid":false,"given":"Hiroshi","family":"Ureshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-6208","authenticated-orcid":false,"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"3155_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"3155_CR2","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TML. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137.","journal-title":"J Clin Oncol"},{"key":"3155_CR3","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797\u2013813.","journal-title":"Leukemia"},{"key":"3155_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon F-X, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029\u201335.","journal-title":"Lancet Oncol"},{"key":"3155_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515\u201322.","journal-title":"Blood"},{"key":"3155_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424\u201330.","journal-title":"J Clin Oncol"},{"key":"3155_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol"},{"key":"3155_CR8","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S2352-3026(19)30168-1","volume":"6","author":"H Ureshino","year":"2019","unstructured":"Ureshino H, Kamachi K, Kimura S. Japan\u2019s high-cost medical expense benefit system could be an obstacle to promoting generic imatinib. Lancet Haematol. 2019;6:e498.","journal-title":"Lancet Haematol"},{"key":"3155_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s12185-019-02613-1","volume":"109","author":"M Kizaki","year":"2019","unstructured":"Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, et al. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. Int J Hematol. 2019;109:426\u201339.","journal-title":"Int J Hematol"},{"key":"3155_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s12185-015-1826-9","volume":"102","author":"H Nakamae","year":"2015","unstructured":"Nakamae H, Yoshida C, Miyata Y, Hidaka M, Uike N, Koga D, et al. A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits. Int J Hematol. 2015;102:304\u201311.","journal-title":"Int J Hematol"},{"key":"3155_CR11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3324\/haematol.2011.056853","volume":"97","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012;97:903\u20136.","journal-title":"Haematologica"},{"key":"3155_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","volume":"107","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2018;107:185\u201393.","journal-title":"Int J Hematol"},{"key":"3155_CR13","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","volume":"103","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103:1835\u201342.","journal-title":"Haematologica"},{"key":"3155_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10147-018-1368-2","volume":"24","author":"S Fujisawa","year":"2019","unstructured":"Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, et al. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int J Clin Oncol. 2019;24:445\u201353.","journal-title":"Int J Clin Oncol"},{"key":"3155_CR15","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2:e528\u201335.","journal-title":"Lancet Haematol"},{"key":"3155_CR16","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","volume":"7","author":"S Kimura","year":"2020","unstructured":"Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020;7:e218\u2013e225.","journal-title":"Lancet Haematol"},{"key":"3155_CR17","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, G\u00f3mez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study. Leukemia. 2017;31:1525\u201331.","journal-title":"Leukemia"},{"key":"3155_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12185-019-02801-z","volume":"111","author":"H Yamaguchi","year":"2020","unstructured":"Yamaguchi H, Takezako N, Ohashi K, Oba K, Kumagai T, Kozai Y, et al. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group. Int J Hematol. 2020;111:401\u20138.","journal-title":"Int J Hematol"},{"key":"3155_CR19","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s12185-023-03549-3","volume":"117","author":"C Yoshida","year":"2023","unstructured":"Yoshida C, Yamaguchi H, Doki N, Murai K, Iino M, Hatta Y, et al. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study. Int J Hematol. 2023;117:694\u2013705.","journal-title":"Int J Hematol"},{"key":"3155_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s12185-026-04184-4","volume":"124","author":"N Takahashi","year":"2026","unstructured":"Takahashi N, Kimura S, Matsuki E, Ono T, Doki N, Iino M, et al. Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan. Int J Hematol. 2026;124:96\u2013103.","journal-title":"Int J Hematol"},{"key":"3155_CR21","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1002\/cncr.30885","volume":"123","author":"L Legros","year":"2017","unstructured":"Legros L, Nicolini FE, \u00c9tienne G, Rousselot P, Rea D, Giraudier S, et al. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer. 2017;123:4403\u201310.","journal-title":"Cancer"},{"key":"3155_CR22","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/bjh.18796","volume":"201","author":"S Dulucq","year":"2023","unstructured":"Dulucq S, Rigal-Huguet F, Nicolini FE, Cony-Makhoul P, Escoffre-Barbe M, Gardembas M, et al. Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: results of the French Nilo post-STIM study. Br J Haematol. 2023;201:1116\u201324.","journal-title":"Br J Haematol"},{"key":"3155_CR23","first-page":"1","volume":"6","author":"MA Perusini","year":"2023","unstructured":"Perusini MA, Novitzky-Basso I, Atenafu EG, Forrest D, Bence-Bruckler I, Savoie L, et al. Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: treatment-free remission accomplished by dasatinib (TRAD) study. Br J Haematol. 2023;6:1\u201311.","journal-title":"Br J Haematol"},{"key":"3155_CR24","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/cas.12216","volume":"104","author":"I Mizoguchi","year":"2013","unstructured":"Mizoguchi I, Yoshimoto T, Katagiri S, Mizuguchi J, Tauchi T, Kimura Y, et al. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci. 2013;104:1146\u201353.","journal-title":"Cancer Sci"},{"key":"3155_CR25","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","volume":"102","author":"D Rea","year":"2017","unstructured":"Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: The IMMUNOSTIM study. Haematologica. 2017;102:1368\u201377.","journal-title":"Haematologica"},{"key":"3155_CR26","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1182\/blood.2020005514","volume":"137","author":"N Shanmuganathan","year":"2021","unstructured":"Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021;137:1196\u2013207.","journal-title":"Blood"},{"key":"3155_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.leukres.2018.01.010","volume":"66","author":"Y Najima","year":"2018","unstructured":"Najima Y, Yoshida C, Iriyama N, Fujisawa S, Wakita H, Chiba S, et al. Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response\u2014the final results of the D-first study. Leuk Res. 2018;66:66\u201372.","journal-title":"Leuk Res"},{"key":"3155_CR28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/cas.13430","volume":"109","author":"T Kumagai","year":"2018","unstructured":"Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018;109:182\u201392.","journal-title":"Cancer Sci"},{"key":"3155_CR29","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1111\/cas.14518","volume":"111","author":"T Kumagai","year":"2020","unstructured":"Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, et al. Silent NK\/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission. Cancer Sci. 2020;111:2923\u201334.","journal-title":"Cancer Sci"},{"key":"3155_CR30","doi-asserted-by":"crossref","unstructured":"Takahashi N, Minami Y, Fujioka Y, Ohtake S, Atsuta Y, Kurata M, et al. Treatment-free remission and immune profiling after frontline second-generation TKI therapy in CML. Blood Adv 2026;10:6255-67.","DOI":"10.1182\/bloodadvances.2026020915"},{"key":"3155_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-026-01526-7","volume":"16","author":"H Ureshino","year":"2026","unstructured":"Ureshino H, Murai K, Kumagai T, Mino T, Nishiwaki K, Wakita S, et al. Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial. Blood Cancer J. 2026;16:83.","journal-title":"Blood Cancer J"},{"key":"3155_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20191009","volume":"217","author":"A Tanaka","year":"2020","unstructured":"Tanaka A, Nishikawa H, Noguchi S, Sugiyama D, Morikawa H, Takeuchi Y, et al. Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. J Exp Med. 2020;217:1\u201314.","journal-title":"J Exp Med"},{"key":"3155_CR33","doi-asserted-by":"crossref","unstructured":"Fujioka Y, Sugiyama D, Matsumura I, Minami Y, Miura M, Atsuta Y, et al. Regulatory T cell as a biomarker of treatment-free remission in patients with chronic myeloid leukemia. Cancers. 2021;13:5904.","DOI":"10.3390\/cancers13235904"},{"key":"3155_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100001","volume":"1","author":"H Ureshino","year":"2024","unstructured":"Ureshino H, Ueda Y, Fujisawa S, Usuki K, Tanaka H, Okada M, et al. KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study. Blood Neoplasia. 2024;1:100001.","journal-title":"Blood Neoplasia"},{"key":"3155_CR35","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1158\/2326-6066.CIR-17-0462","volume":"6","author":"H Ureshino","year":"2018","unstructured":"Ureshino H, Shindo T, Kojima H, Kusunoki Y, Miyazaki Y, Tanaka H, et al. Allelic polymorphisms of KIR s and HLA s predict favorable responses to tyrosine kinase inhibitors in CML. Cancer Immunol Res. 2018;6:745\u201354.","journal-title":"Cancer Immunol Res"},{"key":"3155_CR36","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/jha2.1053","volume":"5","author":"H Ureshino","year":"2024","unstructured":"Ureshino H, Kamachi K, Kidoguchi K, Kimura S. IFN-\u03b1 treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CP. EJHaem. 2024;5:1278\u201382.","journal-title":"EJHaem"},{"key":"3155_CR37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41375-025-02859-1","volume":"40","author":"A Burchert","year":"2026","unstructured":"Burchert A, Nicolini FE, le Coutre P, Saussele S, Hochhaus A, Tuere E, et al. Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE\/CML-IX). Leukemia. 2026;40:410\u20137.","journal-title":"Leukemia"},{"key":"3155_CR38","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41375-026-02913-6","volume":"40","author":"M Fujita","year":"2026","unstructured":"Fujita M, Ureshino H. Potential impact of NK-cell education on interferon efficacy in the ENDURE trial. Leukemia. 2026;40:1583\u20134.","journal-title":"Leukemia"},{"key":"3155_CR39","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1038\/bcj.2017.84","volume":"7","author":"M Matsushita","year":"2017","unstructured":"Matsushita M, Ozawa K, Suzuki T, Nakamura M, Nakano N, Kanchi S, et al. CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients. Blood Cancer J. 2017;7:e601\u20137.","journal-title":"Blood Cancer J"},{"key":"3155_CR40","doi-asserted-by":"crossref","unstructured":"Jo T, Saburi Y, Masunari T, Noguchi K, Sakai T, Taguchi J, et al. Activated memory cytotoxic T-lymphocytes and T-cell receptor V\u03b2 clonality predict treatment-free remission after tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia: a 1-year prospective immuno-monitoring study. Int J Mol Sci. 2026;27:2713.","DOI":"10.3390\/ijms27062713"},{"key":"3155_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cam4.71142","volume":"14","author":"H Ureshino","year":"2025","unstructured":"Ureshino H, Nakamura Y, Budirahardja Y, Nozawa I, Kidoguchi K, Kamachi K, et al. Clinical features and T-cell repertoire of chronic myeloid leukemia patients who attempt discontinuation of tyrosine kinase inhibitors: the ISAC-TFR study. Cancer Med. 2025;14:1\u20139.","journal-title":"Cancer Med"},{"key":"3155_CR42","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nature08734","volume":"463","author":"K Naka","year":"2010","unstructured":"Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, et al. TGF-\u0392-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463:676\u201380.","journal-title":"Nature"},{"key":"3155_CR43","doi-asserted-by":"crossref","unstructured":"Naka K, Ochiai R, Matsubara E, Kondo C, Yang KM, Hoshii T, et al. The lysophospholipase D enzyme Gdpd3 is required to maintain chronic myelogenous leukaemia stem cells. Nat Commun 2020;11:4681.","DOI":"10.1038\/s41467-020-18491-9"},{"key":"3155_CR44","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Takeda R, Fukushima T, Mikami K, Tsuchiya S, Tamura M, et al. Eliminating chronic myeloid leukemia stem cells by IRAK1\/4 inhibitors. Nat Commun. 2022;13:271.","DOI":"10.1038\/s41467-021-27928-8"},{"key":"3155_CR45","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3324\/haematol.2019.230227","volume":"106","author":"T Yahata","year":"2021","unstructured":"Yahata T, Ibrahim AA, Hirano K-I, Muguruma Y, Naka K, Hozumi K, et al. Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells. Haematologica. 2021;106:483\u201394.","journal-title":"Haematologica"},{"key":"3155_CR46","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1002\/cam4.5292","volume":"12","author":"N Takahashi","year":"2023","unstructured":"Takahashi N, Kameoka Y, Onizuka M, Onishi Y, Takahashi F, Dan T, et al. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor. Cancer Med. 2023;12:4250\u20138.","journal-title":"Cancer Med"},{"key":"3155_CR47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.canlet.2021.11.032","volume":"526","author":"K Kamachi","year":"2022","unstructured":"Kamachi K, Ureshino H, Watanabe T, Yoshida N, Yamamoto Y, Kurahashi Y, et al. Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitor sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. Cancer Lett. 2022;526:273\u201383.","journal-title":"Cancer Lett"},{"key":"3155_CR48","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846\u201354.","journal-title":"Blood"},{"key":"3155_CR49","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1038\/s41375-025-02769-2","volume":"39","author":"M Purhonen","year":"2025","unstructured":"Purhonen M, Tatun M, Luukkainen K, Hung K, Sundquist H, Tafjord O, et al. Granulocyte abundance and maturation state at diagnosis predict treatment-free remission in CML. Leukemia. 2025;39:2968\u201377.","journal-title":"Leukemia"},{"key":"3155_CR50","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/16078454.2022.2135857","volume":"27","author":"H Ureshino","year":"2022","unstructured":"Ureshino H, Kamachi K, Sano H, Okamoto S, Itamura H, Yoshimura M, et al. Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. Hematology. 2022;27:1171\u20135.","journal-title":"Hematology"},{"key":"3155_CR51","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/ijlh.70062","volume":"48","author":"M Fujita","year":"2026","unstructured":"Fujita M, Ureshino H, Kimura S. Peripheral blood neutrophil maturation as a practical predictor of treatment-free remission in CML. Int J Lab Hematol. 2026;48:664\u20137.","journal-title":"Int J Lab Hematol"},{"key":"3155_CR52","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim D-W, Kim DDH, Mayer J, Goh Y-T, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391:885\u201398.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03155-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03155-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03155-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:12:03Z","timestamp":1791288723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03155-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":52,"alternative-id":["3155"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03155-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"27 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HU declares honoraria from Novartis. SK received honoraria from Pfizer, Otsuka Pharmaceuticals, Novartis and Bristol-Myers-Squibb, and research funding from Pfizer, Bristol-Myers-Squibb and Ohara Pharmaceuticals. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}